Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro

समान संसाधन

• IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors
  द्वारा: Molenaar, Remco J., और अन्य
  प्रकाशित: (2018)
• Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
  द्वारा: Wang, Feng, और अन्य
  प्रकाशित: (2021)
• Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
  द्वारा: Merchant, Shelby L., और अन्य
  प्रकाशित: (2019)
• Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia
  द्वारा: Venugopal, Sangeetha, और अन्य
  प्रकाशित: (2021)
• Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
  द्वारा: Gupta, Charu, और अन्य
  प्रकाशित: (2020)